$FWBI News

Last published 2y ago

2y agoFWBI ENTOFirst Wave BioPharma Changes Name to Entero TherapeuticsGlobeNewswireRebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is "ENTO" effective May 17, 2024 BOCA RATON, Fla.,
2y agoFWBIFirst Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-MarketGlobeNewswireBOCA RATON, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness MonthGlobeNewswireBOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, NutrientsGlobeNewswireBOCA RATON, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap ShowcaseGlobeNewswireBOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders ConferenceGlobeNewswireBOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) ConferenceGlobeNewswirePoster presentations to highlight new quantitative and serologic diagnostic methods for Celiac Disease detection and determination of intestinal mucosal health New tools may serve as companion diagnostics for
2y agoFWBIFirst Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical PipelineGlobeNewswireLatiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave BioPharma; Jack Syage,
2y agoFWBIFirst Wave BioPharma to Participate In 'Fireside Chat' at the 36th Annual Roth ConferenceGlobeNewswireBOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct OfferingGlobeNewswireBOCA RATON, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024GlobeNewswireBOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma to Present at the DealFlow MicroCap ConferenceGlobeNewswireBOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto RicoGlobeNewswireBOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024GlobeNewswireBOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds PricedGlobeNewswireBOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the "Company") (NASDAQ:FWBI), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD ProgramGlobeNewswireBOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical CompanyGlobeNewswirePhase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease, will expand First Wave BioPharma's late-stage gastrointestinal (GI) disease clinical pipeline A concurrent institutional investment and a
2y agoFWBIFirst Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of StockholdersGlobeNewswireBOCA RATON, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma," "First Wave" or the "Company"), a clinical-stage biopharmaceutical company specializing in the
2y agoFWBIFirst Wave BioPharma to Participate in BIO Partnering @JPM During "J.P. Morgan Week 2024"GlobeNewswireBOCA RATON, Fla., Dec. 06, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
2y agoFWBIFirst Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders ConferenceGlobeNewswireBOCA RATON, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIDate and Time Announced for First Wave BioPharma CEO James Sapirstein's Presentation at the 2023 BIO Investor ForumGlobeNewswireBOCA RATON, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma CEO James Sapirstein to Present at the 2023 Roth Healthcare Opportunities ConferenceGlobeNewswireBOCA RATON, Fla., Oct. 03, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma To Present at the BIO Investor ForumGlobeNewswireBOCA RATON, Fla., Sept. 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted,
3y agoFWBIFirst Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-MarketGlobeNewswireBOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the "Company") (NASDAQ:FWBI), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBI SNYFirst Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from SanofiGlobeNewswireBOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted,
3y agoFWBIFirst Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireBOCA RATON, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public OfferingGlobeNewswireBOCA RATON, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase FormulationGlobeNewswireBOCA RATON, Fla., July 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Chairman and CEO Issues Letter to StockholdersGlobeNewswireBOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase FormulationGlobeNewswireBOCA RATON, Fla., June 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Strengthens Intellectual Property EstateGlobeNewswireBOCA RATON, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30)GlobeNewswireBOCA RATON, Fla., June 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-MarketGlobeNewswireBOCA RATON, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the "Company") (NASDAQ:FWBI), a clinical-stage biopharmaceutical company specializing in the development
3y agoFWBIFirst Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic FibrosisGlobeNewswireTwo-thirds of patients have completed study, final patients being dosedTop line data read-out on track for July 2023 BOCA RATON, Fla., June 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave
3y agoFWBI GMDA HOOKGamida Cell Appoints Terry Coelho as CFOBusiness WireIndustry veteran Coelho brings more than 35 years of experience at emerging growth and global companies to role; Shai Lankry to leave company June 2 Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to
3y agoFWBIFirst Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International ConferenceGlobeNewswireBOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic FibrosisGlobeNewswireTop line data read-out on track for July 2023 BOCA RATON, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the "Company") (NASDAQ:FWBI), a clinical-stage
3y agoFWBIFirst Wave BioPharma to Participate in EF Hutton Inaugural Global ConferenceGlobeNewswireBOCA RATON, Fla., May 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic FibrosisGlobeNewswireThree U.S. clinical trial sites actively screening and enrolling patientsTop line data of adrulipase in Cystic Fibrosis patients expected in July 2023 BOCA RATON, Fla., April 25, 2023 (GLOBE NEWSWIRE) -- First Wave
3y agoFWBIFirst Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq RulesGlobeNewswireBOCA RATON, Fla., March 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. ("First Wave BioPharma" or the "Company") (NASDAQ:FWBI), a clinical-stage biopharmaceutical company specializing in the
3y agoFWBI HOOKHOOKIPA Pharma Appoints Terry Coelho to its Board of DirectorsGlobeNewswireNEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced
3y agoFWBIFirst Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic FibrosisGlobeNewswireBOCA RATON, Fla., March 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase FormulationGlobeNewswireBOCA RATON, Fla., March 09, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma to Participate in 'Fireside Chat' at the 35th Annual Roth ConferenceGlobeNewswireBOCA RATON, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) ConferenceGlobeNewswireBOCA RATON, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Chairman and CEO Issues Letter to StockholdersGlobeNewswireBOCA RATON, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Regains Compliance With Nasdaq's Minimum Bid Price RequirementGlobeNewswireBOCA RATON, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic FibrosisGlobeNewswireBOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic FibrosisGlobeNewswireBOCA RATON, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of
3y agoFWBIFirst Wave BioPharma to Present at the BIO CEO & Investor ConferenceGlobeNewswireBOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of